arrow
G

Gunnar Folprecht

universitaetsklinikum carl gustav carus
H指数:54
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Chemotherapy for patients with circulating tumour DNA positive, stage II colon cancer (CIRCULATE) – an AIO / ABCSG trial

循环肿瘤DNA阳性、II期结肠癌患者的化疗(CIRCULATE)——一项AIO/ABCSG试验

2026-05-310
OAAI
Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC)

度鲁妥单抗和特瑞普利单抗联合局部部分肿瘤消融(射频消融或立体定向放疗)在转移性结直肠癌不可切除性肝转移患者中的应用:EORTC-1560-GITCG多中心、单臂II期研究(ILOC)的结果

2025-07-230
PREAI
Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials

脂质体伊立替康(nal-IRI)联合氟尿嘧啶(5-FU)和亚叶酸钙(LV)对比5-FU/LV单药治疗在吉西他滨为基础治疗后进展的晚期胆道癌(BTC)中的有效性和安全性:NIFTY和NALIRICC试验的合并分析

2024-09-010
PRE
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC) a multicentre, open-label, randomised, phase 2 trial
2024-08-013
OAAI
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy
2024-03-066
OA
Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold

使用基于患者的类器官阈值对食管-胃癌治疗进行分层

2024-01-107
OAAI
Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial
2023-10-013
OAAI
Integrating trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2+gastric cancer (GC) - subgroup analyses of EORTC 1203 INNOVATION, a collaboration with KCSG and DUCG
2023-06-012
OA
Novel data visualization and unsupervised machine learning techniques to support optimal management of toxicity profiles of encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer

新型数据可视化和无监督机器学习技术支持BRAFV600E-mutant转移性结直肠癌患者对恩可非尼加西妥昔单抗毒性谱的优化管理

2023-06-010
OA
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers
2022-11-0128
OA
Bcl-xL as prognostic marker and potential therapeutic target in cholangiocarcinoma

Bcl-xl作为胆管癌的预后标志物和潜在治疗靶点

2022-09-147
OAAI
Gene expression-based prediction of pazopanib efficacy in sarcoma
2022-09-014
PRE
Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly- informed therapies despite heterogeneity
2022-08-0227
OAAI
Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment

检测胰腺癌类器官的耐药性指导优化化疗治疗

2022-05-0521
OAAI